--- title: "Atea Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286155927.md" datetime: "2026-05-12T20:48:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286155927.md) - [en](https://longbridge.com/en/news/286155927.md) - [zh-HK](https://longbridge.com/zh-HK/news/286155927.md) --- # Atea Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.57, beating the estimate of USD -0.59. EBIT: As of FY2026 Q1, the actual value is USD -48.01 M. Atea Pharmaceuticals, Inc. operates as one operating segment focused on discovering, developing, and commercializing antiviral therapeutics, and has not generated any product revenue since its inception, with no anticipated revenue from product sales for the foreseeable future . #### Financial Performance - **Net Loss**: Atea Pharmaceuticals, Inc. reported a net loss of - $45.4 million for the three months ended March 31, 2026, compared to - $34.3 million for the three months ended March 31, 2025 . - **Loss from Operations**: The loss from operations was - $48.0 million for the three months ended March 31, 2026, an increase from - $39.0 million for the same period in 2025 . - **Total Operating Expenses**: Total operating expenses increased to $48.0 million for the three months ended March 31, 2026, from $39.0 million for the three months ended March 31, 2025 . - **Research and Development Expenses**: Research and development expenses increased by $11.6 million, from $29.6 million for the three months ended March 31, 2025, to $41.1 million for the three months ended March 31, 2026 . This increase was primarily driven by higher external spend for HCV Phase 3 clinical development and HEV preclinical development activities, partially offset by lower internal research and development expenses . - HCV external costs were $29.3 million in Q1 2026, up from $17.6 million in Q1 2025 . - HEV external costs were $4.0 million in Q1 2026, compared to $0 in Q1 2025 . - COVID-19 external costs decreased to $0 in Q1 2026 from $1.2 million in Q1 2025 . - Early stage discovery external costs decreased to $0 in Q1 2026 from $0.3 million in Q1 2025 . - Compensation and related expenses for R&D were $4.9 million in Q1 2026, down from $6.0 million in Q1 2025 . - **General and Administrative Expenses**: General and administrative expenses decreased by $2.6 million, from $9.5 million for the three months ended March 31, 2025, to $6.9 million for the three months ended March 31, 2026 . This decrease was mainly due to lower salaries and wages, lower stock-based compensation, and lower professional fees . - Compensation and related expenses for G&A were $2.4 million in Q1 2026, down from $2.7 million in Q1 2025 . - Consulting and professional fees for G&A were $2.4 million in Q1 2026, down from $2.9 million in Q1 2025 . - **Interest Income and Other, Net**: Interest income and other, net, decreased to $2.6 million for the three months ended March 31, 2026, from $5.0 million for the same period in 2025, primarily due to lower investment balances . - **Income Tax Expense**: Income tax expense was - $0.1 million for Q1 2026 and - $0.2 million for Q1 2025 . #### Liquidity and Capital Resources - **Cash, Cash Equivalents and Marketable Securities**: As of March 31, 2026, Atea Pharmaceuticals, Inc. had $256.0 million in cash, cash equivalents, and marketable securities, down from $301.8 million as of December 31, 2025 . - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $46.4 million for the three months ended March 31, 2026, compared to - $30.6 million for the same period in 2025 . - **Net Cash Provided by Investing Activities**: Net cash provided by investing activities was $29.7 million for the three months ended March 31, 2026, compared to $85.6 million for the same period in 2025 . - **Net Cash Provided by (Used in) Financing Activities**: Net cash provided by financing activities was $0.3 million for the three months ended March 31, 2026, compared to - $0.3 million used in the same period in 2025 . #### Outlook and Strategy Atea Pharmaceuticals, Inc. expects topline results from its C-BEYOND Phase 3 clinical trial in mid-2026 and C-FORWARD trial at year-end 2026, targeting a New Drug Application (NDA) submission in March 2027 for its HCV regimen, while initiating clinical development for its HEV program in mid-2026 . The company anticipates its existing financial resources will fund operations through at least March 31, 2027, and through 2027 to complete the HCV Phase 3 program . Atea Pharmaceuticals, Inc. also has an open market sales agreement for up to $200.0 million in common stock and remains open to strategic transactions . ### Related Stocks - [AVIR.US](https://longbridge.com/en/quote/AVIR.US.md) ## Related News & Research - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)